Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID) [Yahoo! ...
Jaguar Health, Inc. (JAGX)
US:NASDAQ Investor Relations:
jaguarhealth.gcs-web.com/investor-overview
Company Research
Source: Yahoo! Finance
Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress , which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE). Additionally, at the conference Napo is sponsoring a panel discussion titled "Masterclass in Congenital Diarrhea" which will focus on microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder. Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for both MVID and short bowel syndrome (SBS) with intestinal failure. "As previously announced, Jaguar, with strong leadership and participation from Jaguar family companies Napo Pharmaceuticals and Napo Therapeutics, is s
Show less
Read more
Impact Snapshot
Event Time:
JAGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAGX alerts
High impacting Jaguar Health, Inc. news events
Weekly update
A roundup of the hottest topics
JAGX
News
- Jaguar Health Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Reports First Quarter 2024 Financial ResultsAccesswire
- REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate UpdatesAccesswire
- Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in EuropeAccesswire
JAGX
Sec Filings
- 5/14/24 - Form 10-Q
- 5/10/24 - Form PRE
- 5/2/24 - Form EFFECT
- JAGX's page on the SEC website